Authors:
Burke, TA
Zabinski, RA
Pettitt, D
Maniadakis, N
Maurath, CJ
Goldstein, JL
Citation: Ta. Burke et al., A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis, PHARMACOECO, 19(1), 2001, pp. 33-47
Authors:
Zabinski, RA
Burke, TA
Johnson, J
Lavoie, F
Fitzsimon, C
Tretiak, R
Chancellor, JVM
Citation: Ra. Zabinski et al., An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada, PHARMACOECO, 19(1), 2001, pp. 49-58
Citation: Jm. Samet et Ta. Burke, The Bush administration, the environment and public health - warnings fromthe first 100 days, INT J EPID, 30(4), 2001, pp. 658-660
Authors:
Bensen, WG
Zhao, SZ
Burke, TA
Zabinski, RA
Makuch, RW
Maurath, CJ
Agrawal, NM
Geis, GS
Citation: Wg. Bensen et al., Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo, J RHEUMATOL, 27(8), 2000, pp. 1876-1883
Citation: Nl. Tran et al., Chemical and radiation environmental risk management: Differences, commonalities, and challenges, RISK ANAL, 20(2), 2000, pp. 163-172
Authors:
Burke, TA
McKee, JR
Pathak, DS
Donahue, RMJ
Parasuraman, TV
Batenhorst, AS
Citation: Ta. Burke et al., Costs of epilepsy in an intermediate care facility for persons with mentalretardation, AM J MENT R, 104(2), 1999, pp. 148-157